JPH10501541A - 新規のトロンビン阻害剤、その製造方法及び使用 - Google Patents
新規のトロンビン阻害剤、その製造方法及び使用Info
- Publication number
- JPH10501541A JPH10501541A JP8501568A JP50156896A JPH10501541A JP H10501541 A JPH10501541 A JP H10501541A JP 8501568 A JP8501568 A JP 8501568A JP 50156896 A JP50156896 A JP 50156896A JP H10501541 A JPH10501541 A JP H10501541A
- Authority
- JP
- Japan
- Prior art keywords
- pro
- boc
- phe
- group
- pamb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式: [式中、置換基は以下のものを表す: (この場合、前記の全てのA基において、α−NH基又はα−NH2基は、C1-1 2 −アルキル、フェニル−C1-4−アルキレン、X12OC−C1-6−アルキレン、 X12OC−C1-6−アルキルカルボニル、α−もしくはβ−ナフチル−C1-4−ア ルキレン、C1-12−アルキルカルボニル、フェニル−C1-4−アルキルカルボ ニル、C1-7−アルコキシカルボニル、フェニル−C1-5−アルコキシカルボニル 、α−もしくはβ−ナフチル−C1-4−アルキルカルボニル、C1-6−アルキルア ミノカルボニル又はフェニル−C1-4−アルキルアミノカルボニルにより一置換 もしくは二置換されていてもよい)、 更にA:X1-NH-CH2-CH2-CO-,X1-NH-CH2-CH2-CH2-CO-,X15-(CH2)f-SO2-(f =0,1,2,3,4、X15=場合により1-3個のCH3基及び/又はCH3O 基により置換されたフェニル基又はα−もしくはβ−ナフチル基又は以下の基の 1つ: 更にA: X18-O-CO-C1-4−アルキレン-CO-(X18=H,C1-4 −アルキル)、C1-12−アルキル−CO−、C1-10−アルキル−NH−CO−、 フェニル−C1-4−アルキレン−NH−CO−、α−又はβ−ナフチル−CO− 又はC3-7-シクロアルキル−CO−、 (X18=H又はC1-4−アルキル、 X19=H、C1-6−アルキル、フェニル、ベンジル、シクロヘキシル又はシク ロヘキシルメチル) R1:H又はC1-4−アルキル、 R2:H又はC1-4−アルキル、 R3:H、C1-8−アルキル、フェニル、フェニル−C1-4−アルキレン、CH2 OH、−CO−X20、CO−CO−X20(X20=H,C1-4−アルコキシ、C1-4 −アルキル、フェニル、フェニル−C1-4−アルキレン、フェニル−C1-4−アル コキシ、CF3、C2F5、N末結合した天然アミノ酸、CH2OH、−CH2−O −C1-4−アルキル、−NH−(C1-4−アルキレン)−フェニル又はNH−C1- 6 −アルキル)、 m:0,1,2又は3、 D:フェニレン、該基には(CH2)m及び(NH)nがパラ−又はメタ位に互 いに結合されかつ(CH2)m に対してオルト位でF,Cl,Br,HO−CH2−,OH,NH2,NO2,C1-4 −アルコキシ、C1-6−アルキル又はCOX21(X21=H、C1-4−アルキル 、C1-4−アルコキシ、OH、NH2、NH−C1-4−アルキル)、-O-(CH2)1-3-C O-X21又は-(CH2)1-3-CO-X21により置換されていてもよい、 ピリジニレン、ピリミジニレン、ピラジニレン又はピリダジニレン、これらの 基には(CH2)m及び(NH)nがパラ−又はメタ位に互いに結合されておりか つこれらの基は(CH2)mに対してオルト位でF,Cl,Br、OH,NH2, NO2,C1-4−アルコキシ又はC1-6−アルキルにより置換されていてもよい、 1,4−又は1,3−シクロヘキシレン、該基おいて(CH2)mに対するオル ト位のCH2基はNH,O,S又はSOにより置換されていてもよい、又は ピペリジニレン、該基は窒素の対して3位又は4位で(CH2)mと結合されて おり、かつ該基中窒素原子自体はC(=NH)NHR4基を有する、 n:0又は1、 R4:H,−CO−C1-20−アルキル、OH又はNH2]で示される化合物並び にその生理学的に認容される酸との塩及びその立体異性体。 2.疾病をコントロールする際に使用するための請求項1記載の式Iの化合物 。 3.式II: [式中、R1,R2,R3及びDは式Iのために記載したものを表し、かつ R5:H,C1-4−アルコキシ−CO−又はフェニル−C1-3−アルコキシ−C O−、 R6:C(R2,R3)に対するm−位又はp−位におけるシアノ基、アミジノ 基又はグアニジノ基及び p:1,2又は3 を表す]で示される化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4421052A DE4421052A1 (de) | 1994-06-17 | 1994-06-17 | Neue Thrombininhibitoren, ihre Herstellung und Verwendung |
DE4421052.3 | 1994-06-17 | ||
PCT/EP1995/002135 WO1995035309A1 (de) | 1994-06-17 | 1995-06-06 | Neue thrombininhibitoren, ihre herstellung und verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10501541A true JPH10501541A (ja) | 1998-02-10 |
Family
ID=6520741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8501568A Pending JPH10501541A (ja) | 1994-06-17 | 1995-06-06 | 新規のトロンビン阻害剤、その製造方法及び使用 |
Country Status (26)
Country | Link |
---|---|
US (3) | US6455671B1 (ja) |
EP (1) | EP0773955B1 (ja) |
JP (1) | JPH10501541A (ja) |
CN (1) | CN1189476C (ja) |
AT (1) | ATE237631T1 (ja) |
AU (1) | AU699501B2 (ja) |
BR (1) | BR9508057A (ja) |
CA (1) | CA2193133A1 (ja) |
CZ (1) | CZ293426B6 (ja) |
DE (2) | DE4421052A1 (ja) |
DK (1) | DK0773955T3 (ja) |
ES (1) | ES2197200T3 (ja) |
FI (1) | FI965039A (ja) |
HR (1) | HRP950338B1 (ja) |
HU (1) | HUT78040A (ja) |
IL (1) | IL114127A (ja) |
MX (1) | MX9606521A (ja) |
NO (1) | NO965412L (ja) |
NZ (1) | NZ288591A (ja) |
PL (1) | PL181405B1 (ja) |
PT (1) | PT773955E (ja) |
RU (1) | RU2172741C2 (ja) |
SI (1) | SI9520075B (ja) |
TW (1) | TW458986B (ja) |
WO (1) | WO1995035309A1 (ja) |
ZA (1) | ZA954972B (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5726159A (en) * | 1994-03-04 | 1998-03-10 | Eli Lilly And Company | Antithrombotic agents |
US5707966A (en) * | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
US5705487A (en) * | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
CN1198839C (zh) * | 1995-02-17 | 2005-04-27 | 艾伯特有限及两合公司 | 作为凝血酶抑制剂的新的二肽脒类 |
US5914319A (en) * | 1995-02-27 | 1999-06-22 | Eli Lilly And Company | Antithrombotic agents |
US5710130A (en) * | 1995-02-27 | 1998-01-20 | Eli Lilly And Company | Antithrombotic agents |
CA2176414A1 (en) * | 1995-05-18 | 1996-11-19 | S. David Kimball | Acyl guanidine and amidine prodrugs |
SA96170106A (ar) * | 1995-07-06 | 2005-12-03 | أسترا أكتيبولاج | مشتقات حامض أميني جديدة |
GB9526273D0 (en) * | 1995-12-21 | 1996-02-21 | Astra Ab | New prodrugs |
TW541316B (en) * | 1995-12-21 | 2003-07-11 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
CN1211991A (zh) * | 1995-12-22 | 1999-03-24 | 诺沃挪第克公司 | 具有生长激素释放性质的化合物 |
US5942544A (en) * | 1996-02-22 | 1999-08-24 | Dupont Pharmaceuticals Company | α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors |
US5811402A (en) * | 1996-03-22 | 1998-09-22 | Eli Lilly And Company | Antithrombotic diamides |
SE9602263D0 (sv) | 1996-06-07 | 1996-06-07 | Astra Ab | New amino acid derivatives |
KR100483869B1 (ko) * | 1996-06-07 | 2005-09-09 | 아스트라제네카 악티에볼라그 | 신규한 아미노산 유도체 및 트롬빈 억제제로서의 그의 용도 |
US5863929A (en) | 1996-06-25 | 1999-01-26 | Eli Lilly And Company | Anticoagulant agents |
US6200967B1 (en) | 1996-06-25 | 2001-03-13 | Eli Lilly And Company | Anticoagulant agents |
SE9602646D0 (sv) | 1996-07-04 | 1996-07-04 | Astra Ab | Pharmaceutically-useful compounds |
DE19632773A1 (de) * | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Thrombininhibitoren |
DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
AR013084A1 (es) | 1997-06-19 | 2000-12-13 | Astrazeneca Ab | Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados |
SE9704543D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Ab | New compounds |
BR9907112A (pt) * | 1998-01-26 | 2000-10-24 | Basf Ag | Composto, medicamento, e, uso de um composto |
US6291514B1 (en) * | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
IL139162A0 (en) | 1998-04-24 | 2001-11-25 | Dimensional Pharm Inc | Amidinohydrazone, alkoxyguanidine and aminoguanidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
SE9804313D0 (sv) | 1998-12-14 | 1998-12-14 | Astra Ab | New compounds |
ES2295004T3 (es) | 1999-01-13 | 2008-04-16 | Astrazeneca Ab | Nuevos derivados amidinobencilaminicos y su uso como inhibidores de trombina. |
PL352834A1 (en) * | 1999-04-09 | 2003-09-08 | Abbott Gmbh & Co.Kg | Prodrugs of thrombin inhibitors |
TR200102913T2 (tr) | 1999-04-09 | 2002-01-21 | Basf Aktiengesellschaft | Tam proteazların düşük moleküler ağırlıklı inhibitörleri. |
AR023510A1 (es) | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
SE0001803D0 (sv) | 2000-05-16 | 2000-05-16 | Astrazeneca Ab | New compounds i |
US6433186B1 (en) | 2000-08-16 | 2002-08-13 | Astrazeneca Ab | Amidino derivatives and their use as thormbin inhibitors |
DE10049937A1 (de) * | 2000-10-06 | 2002-04-11 | Knoll Ag | Niedermolekulare Inhibitoren von Serinproteasen mit Polyhydroxyalkyl- und Polyhydroxycycloalkylresten |
US7129233B2 (en) | 2000-12-01 | 2006-10-31 | Astrazeneca Ab | Mandelic acid derivatives and their use as thrombin inhibitors |
AR035216A1 (es) * | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
DE10064797A1 (de) * | 2000-12-22 | 2002-06-27 | Knoll Ag | Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon |
DE10117730A1 (de) * | 2001-04-09 | 2002-10-10 | Basf Ag | Umsetzung von (Di)Aminen in Gegenwart einer Lysinoxidase und eines Reduktionsmittels |
AR034517A1 (es) | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
SE0201661D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
SE0201659D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Modified release pharmaceutical formulation |
US7781424B2 (en) | 2003-05-27 | 2010-08-24 | Astrazeneca Ab | Modified release pharmaceutical formulation |
US7795205B2 (en) | 2004-04-12 | 2010-09-14 | Canyon Pharmaceuticals, Inc. | Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor |
US8257648B2 (en) | 2004-12-21 | 2012-09-04 | Scott Elrod | System and method for reducing odors in a blind |
DE102005025728A1 (de) * | 2005-06-04 | 2006-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester |
US7524354B2 (en) * | 2005-07-07 | 2009-04-28 | Research Foundation Of State University Of New York | Controlled synthesis of highly monodispersed gold nanoparticles |
TW200827336A (en) | 2006-12-06 | 2008-07-01 | Astrazeneca Ab | New crystalline forms |
US20090061000A1 (en) * | 2007-08-31 | 2009-03-05 | Astrazeneca Ab | Pharmaceutical formulation use 030 |
WO2011120040A2 (en) * | 2010-03-26 | 2011-09-29 | Matrix Pharma Inc. | Thrombin inhibiting compositions |
JP2012049597A (ja) * | 2010-08-24 | 2012-03-08 | Nikon Corp | 撮像装置 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU178398B (en) | 1979-06-12 | 1982-04-28 | Gyogyszerkutato Intezet | Process for producing new agmatine derivatives of activity against haemagglutination |
GB8305985D0 (en) | 1983-03-04 | 1983-04-07 | Szelke M | Enzyme inhibition |
HU192646B (en) | 1984-12-21 | 1987-06-29 | Gyogyszerkutato Intezet | Process for preparing new n-alkyl-peptide aldehydes |
CA1341029C (en) | 1985-02-04 | 2000-06-20 | Michael Kolb | Peptidase inhibitors |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
EP0362002B1 (en) | 1988-09-01 | 1995-07-26 | Merrell Dow Pharmaceuticals Inc. | HIV protease inhibitors |
ZA897515B (en) | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
ZA905737B (en) | 1989-07-26 | 1991-05-29 | Merrell Dow Pharma | Novel peptidase inhibitors |
GB9017694D0 (en) | 1990-08-13 | 1990-09-26 | Sandoz Ltd | Improvements in or relating to organic chemistry |
IL99527A (en) | 1990-09-28 | 1997-08-14 | Lilly Co Eli | Tripeptide antithrombotic agents |
SE9003534D0 (sv) | 1990-11-06 | 1990-11-06 | Kabigen Ab | A method for isolating and purifying peptides and proteins |
CA2073776A1 (en) * | 1990-11-15 | 1992-05-16 | Joerg Stuerzebecher | Meta-substituted phenyl alanine derivatives |
EP0503203A1 (en) | 1991-03-15 | 1992-09-16 | Merrell Dow Pharmaceuticals Inc. | Novel thrombin inhibitors |
DE4115468A1 (de) * | 1991-05-11 | 1992-11-12 | Behringwerke Ag | Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien |
CA2075154A1 (en) | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Peptide aldehydes as antithrombotic agents |
SE9102462D0 (sv) | 1991-08-28 | 1991-08-28 | Astra Ab | New isosteric peptides |
ZA928581B (en) | 1991-11-12 | 1994-05-06 | Lilly Co Eli | Antithrombotic agents |
SE9103612D0 (sv) | 1991-12-04 | 1991-12-04 | Astra Ab | New peptide derivatives |
WO1993015756A1 (en) | 1992-02-14 | 1993-08-19 | Corvas International, Inc. | Inhibitors of thrombosis |
ES2110599T3 (es) | 1992-03-04 | 1998-02-16 | Gyogyszerkutato Intezet | Nuevos derivados de peptidos anticoagulantes y composiciones farmaceuticas que contienen los mismos, asi como un proceso para su preparacion. |
FR2695562B1 (fr) | 1992-09-11 | 1994-10-14 | Synthelabo | Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un médicament à activité thrombolytique. |
US5371072A (en) | 1992-10-16 | 1994-12-06 | Corvas International, Inc. | Asp-Pro-Arg α-keto-amide enzyme inhibitors |
AU675981B2 (en) | 1992-12-02 | 1997-02-27 | Bristol-Myers Squibb Company | Guanidinyl-substituted heterocyclic thrombin inhibitors |
US5783563A (en) * | 1993-06-03 | 1998-07-21 | Astra Aktiebolag | Method for treatment or prophylaxis of venous thrombosis |
SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
EP0648780A1 (en) | 1993-08-26 | 1995-04-19 | Bristol-Myers Squibb Company | Heterocyclic thrombin inhibitors |
AU1025795A (en) | 1994-01-27 | 1995-08-03 | Mitsubishi Chemical Corporation | Prolineamide derivatives |
US5705487A (en) | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
ZA951617B (en) | 1994-03-04 | 1997-02-27 | Lilly Co Eli | Antithrombotic agents. |
US5726159A (en) | 1994-03-04 | 1998-03-10 | Eli Lilly And Company | Antithrombotic agents |
US5710130A (en) | 1995-02-27 | 1998-01-20 | Eli Lilly And Company | Antithrombotic agents |
GB2302231B (en) * | 1995-03-14 | 1999-01-13 | Matsushita Electric Ind Co Ltd | Speaker system |
-
1994
- 1994-06-17 DE DE4421052A patent/DE4421052A1/de not_active Withdrawn
-
1995
- 1995-06-06 JP JP8501568A patent/JPH10501541A/ja active Pending
- 1995-06-06 DE DE59510645T patent/DE59510645D1/de not_active Revoked
- 1995-06-06 ES ES95923231T patent/ES2197200T3/es not_active Expired - Lifetime
- 1995-06-06 SI SI9520075A patent/SI9520075B/sl not_active IP Right Cessation
- 1995-06-06 RU RU97100941/04A patent/RU2172741C2/ru not_active IP Right Cessation
- 1995-06-06 PL PL95317989A patent/PL181405B1/pl not_active IP Right Cessation
- 1995-06-06 WO PCT/EP1995/002135 patent/WO1995035309A1/de not_active Application Discontinuation
- 1995-06-06 AT AT95923231T patent/ATE237631T1/de not_active IP Right Cessation
- 1995-06-06 CA CA002193133A patent/CA2193133A1/en not_active Abandoned
- 1995-06-06 DK DK95923231T patent/DK0773955T3/da active
- 1995-06-06 BR BR9508057A patent/BR9508057A/pt not_active Application Discontinuation
- 1995-06-06 EP EP95923231A patent/EP0773955B1/de not_active Revoked
- 1995-06-06 US US08/682,604 patent/US6455671B1/en not_active Expired - Lifetime
- 1995-06-06 CN CNB951942123A patent/CN1189476C/zh not_active Expired - Fee Related
- 1995-06-06 MX MX9606521A patent/MX9606521A/es not_active IP Right Cessation
- 1995-06-06 HU HU9603474A patent/HUT78040A/hu unknown
- 1995-06-06 PT PT95923231T patent/PT773955E/pt unknown
- 1995-06-06 NZ NZ288591A patent/NZ288591A/xx not_active IP Right Cessation
- 1995-06-06 AU AU27875/95A patent/AU699501B2/en not_active Ceased
- 1995-06-06 CZ CZ19963713A patent/CZ293426B6/cs not_active IP Right Cessation
- 1995-06-13 IL IL11412795A patent/IL114127A/en not_active IP Right Cessation
- 1995-06-14 HR HR950338A patent/HRP950338B1/xx not_active IP Right Cessation
- 1995-06-15 ZA ZA954972A patent/ZA954972B/xx unknown
- 1995-06-16 TW TW084106192A patent/TW458986B/zh active
-
1996
- 1996-12-16 FI FI965039A patent/FI965039A/fi not_active IP Right Cessation
- 1996-12-16 NO NO965412A patent/NO965412L/no not_active Application Discontinuation
-
2002
- 2002-04-29 US US10/133,384 patent/US20030004308A1/en not_active Abandoned
-
2004
- 2004-10-25 US US10/973,643 patent/US20060111553A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10501541A (ja) | 新規のトロンビン阻害剤、その製造方法及び使用 | |
US6030972A (en) | Dipeptide amidines as thrombin inhibitors | |
US5939392A (en) | Method of thrombin inhibition | |
JPH10513462A (ja) | トロンビンインヒビター | |
EP0956294B1 (de) | Thrombininhibitoren | |
US5780631A (en) | Starting materials in the synthesis of thrombin and kininogenase inhibitors | |
JPH10509727A (ja) | N−末端スルホニル−又はアミノスルホニル基を有する新規のジペプチドのp−アミノベンジルアミド | |
US6984627B1 (en) | Peptide derivatives | |
EP0832879A1 (en) | Process for preparing intermediates for thrombin inhibitors | |
AU684086C (en) | New peptide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060905 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060825 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061201 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070302 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070612 |